5-溴-n-丙基噻吩-2-羧酰胺 | 908494-85-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-溴-n-丙基噻吩-2-羧酰胺
• 英文名称: 5-bromo-N-propylthiophene-2-carboxamide
• CAS: 908494-85-9
• 化学式: C₈H₁₀BrNOS
• mdl: MFCD08593343
• 分子量: 248.143
• InChiKey: YRLNOXHJFHHLRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  57.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  申请人：Collingwood Stephen Paul

  公开号：US20100041887A1

  公开（公告）日：2010-02-18

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的化合物，其以盐或双离子形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉乙酰胆碱M3受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Quinuclidine derivatives binding to mucarinic m3 receptors
  申请人：Collingwood Paul Stephen

  公开号：US20070060563A1

  公开（公告）日：2007-03-15

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的盐或双电离形式的化合物，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉型M3受体介导的病症。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• SMALL MOLECULE INHIBITORS OF PLASMODIUM FALCIPARUM DIHYDROOROTATE DEHYDROGENASE
  申请人：Bastos Cecilia

  公开号：US20110130381A1

  公开（公告）日：2011-06-02

  Inhibitors of dihydroorotate dehydrogenase (DHODH) for the Plasmodium enzyme have been identified and characterized. The inhibitors have high specificity, submicromolar efficacy against cultured parasite strains, exhibit drug-like properties, and are not overtly cytotoxic.

  已经鉴定和表征了针对疟原虫酶的脱氢脱氧尿嘧啶酸脱氢酶（DHODH）抑制剂。这些抑制剂具有高度特异性，在培养的寄生虫株中具有亚微摩尔效力，具有类似药物的特性，并且不明显细胞毒性。
• US8168654B2
  申请人：——

  公开号：US8168654B2

  公开（公告）日：2012-05-01
• US8703811B2
  申请人：——

  公开号：US8703811B2

  公开（公告）日：2014-04-22